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Abstract: A novel positive-sense RNA virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 
was identified in December 2019 in China. It is a systemic disease that includes severe respiratory distress, coronavirus 
disease 19 (Covid-19). The primary way of transmitting this virus is person-to-person contact via respiratory droplets, but 
it can also be transmitted by contaminated surfaces. Symptoms range from mild to severe, and the virus spreads quickly. 
On 11 March 2020 Covid-19 was declared a pandemic by the World Health Organization. The standard way to identify 
the presence of the virus is to detect its genome using real-time reverse transcriptase polymerase chain reaction (RT-
PCR). It can be applied to respiratory tract samples such as nasopharyngeal swabs, sputum and bronchoalveolar lavage. 
In order to identify contact with the virus and immunological response of the individual, tests based on immunoassays 
were developed. Many of those tests were produced in short periods of time and they mostly differ on the sample that can 
be used (serum, plasma or whole blood), complexity and/or expense, and the class of the antibody they detect. The 
reliability of such tests is of high importance for epidemiological surveys as well as for the development of a vaccine. 
The aim of this study was to compare three commercially available immunoassay tests. Our results show that different 
serological tests have different sensitivity and specificity, and that the rapid option, which is the easiest to perform and 
has the lowest cost, provides the least reliable results. 
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INTRODUCTION 
The novel Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) was identified in 
December 2019 in Wuhan City, Hubei Province of 
China. It is a positive-sense RNA virus which causes 
respiratory distress, a disease that has been called 
coronavirus disease 19 (Covid-19). It is believed that the 
virus spread from China all over the world, so on 11 
March 2020 Covid-19 was declared as a pandemic by 
the World Health Organization (WHO).1 Since the 
beginning of the pandemic until today (28/08/2020), 
Croatia has had 9,192 cases of SARS-CoV-2 infection, 
6,595 people have fully recovered and 177 people died.2 
Contact person-to-person via respiratory droplets is the 
primary way of transmitting the SARS-CoV-2, but it can 
also be transmitted by contaminated surfaces. The most 
common symptoms for Covid-19 are fever, dry cough, 
fatigue and muscle pain, loss of taste or smell or 
sometimes also headache and lymphopenia. They 
appear after an incubation period of 2 - 14 days, but there 
are many asymptomatic cases in which people are also 
contagious. The patient’s condition later depends on 
their immunity, health, other comorbidities, and age, and 
can, for example, vary from breathing difficulties and an 
acute respiratory distress syndrome (ARDS), 
pneumonia and other functional failure to death.3 
Real-time RT-PCR is the best method of detecting the 
RNA of the virus in respiratory tract samples such as 
nasopharyngeal swabs, sputum and bronchoalveolar 
lavage of infected patients.4 Positive detection rates are 
different for those sample types, and Yang et al. 
recommend sputum or nasal swabs for accurate 
diagnosis, while they stated that throat swabs were the 
least accurate for diagnosis. They also pointed out that, 
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bronchoalveolar lavage.5 Serological tests detect 
antibodies to SARS-CoV-2 and in that way identify 
individuals who were in contact with virus. It was even 
suggested that combining RT-PCR with serological tests 
is optimal for diagnosis of suspected patients.6 Since 
SARS-Cov-2 has spread worldwide, many serological 
tests developed in a short time with the idea of designing 
an easy and fast tool for confirming SARS-CoV-2 
infection, for epidemiological serological surveys, and 
also for possible future development of a vaccine.7 
One of the rapid serological tests for the detection of IgG 
and IgM antibodies to SARS- CoV-2 in different 
samples (human serum, plasma or whole blood) is the 
Keul-o-test SARS-CoV- 2 IgG/IgM chromatographic 
test (Günter Keul GmbH, Germany). This test is based 
on the principle of lateral flow immunoassay 
chromatography and is available in cassette form. It 
takes 10-20 minutes for the test to give results for IgG 
and IgM antibodies detection on the same cassette. 
One of the tests based on an electrochemiluminescence 
immunoassay that can use human serum and plasma as 
samples and detect antibodies to SARS-CoV-2 
regardless of their immunoglobulin class is the 
serological Elecsys Anti-SARS-CoV-2 (Roche 
Diagnostics International Ltd, Switzerland). The test is 
based on the sandwich principle, and it is intended for 
use on immunoassay analyzers. In a validation study 
performed by Roche Diagnostics International and their 
partners, this test demonstrated an overall specificity of 
99.80% and an overall sensitivity of 99.5% for past 
infection in patients at ≥ 14 days after PCR 
confirmation.8 Test results are done in about 1,5 hours, 
and it provides data about total antibodies (IgG and IgM) 
to SARS-CoV-2. 
EDI Novel Coronavirus COVID-19 IgG and IgM 
ELISA tests detect IgG or IgM antibodies to SARS-
CoV-2 only in human serum. Several studies validated 
this test and reported high “true“ vs. low “false“ 
positivity rates demonstrating that these immunoassays 
are suitable for clinical routine, identifying individuals 
with past SARS-CoV-2 infection with sufficient 
specificity and sensitivity.9, 10 Because this method is 
more demanding than those previously mentioned, 
around 4 hours are needed to get a results for specifically 
IgG or IgM antibody class. 
The aim of this study was to compare three 
immunoassays for the detection of IgG and other classes 
of antibodies raised against SARS-CoV-2 that were 
made for different samples. 
 
 
MATERIAL AND METHODS 
Patients 
In the period from May to July 2020, 1874 patients were 
tested for antibodies to SARS-CoV-2 in the laboratory 
of Breyer Polyclinic, of which 32 using a Keul-O-TEST 
SARS-CoV-2 test, 1724 using Elecsys anti-SARS-Cov-
2 and 118 using the EDI Novel Coronavirus COVID-19 
IgG ELISA test. Thirty of them were chosen for this 
study based on the confirmed presence of disease, 
clinical data and presence of IgG antibodies to SARS-
COV-2 detection using the ELISA-based test (Table 1). 
All patients signed an informed consent form. 
After blood was drawn and centrifuged, serum samples 
from those 30 patients were tested using the rapid Keul-





All three tests represent immunoassay-based methods 
for the detection of anti-SARS-CoV-2 antibodies. Their 
main differences are the type of sample they use, the 
complexity of the method itself and the cost. 
 
 
EDI NOVEL CORONAVIRUS COVID-19 IgG ELISA 
ELISA is done in microtiter wells of a microplate that is 
coated with COVID-19 recombinant nucleocapsid 
protein. Assay controls and 1:100 diluted human serum 
samples are added to the wells. After the first incubation 
period, the unbound protein matrix is removed with a 
wash step. Then, a horseradish peroxidase (HRP) 
labeled polyclonal goat anti-human IgG tracer antibody 
is added to each well. After an incubation period, an 
immunocomplex is formed if there is specific 
coronavirus IgG antibody present in the tested 
specimen. The unbound tracer antibody is removed by 
the subsequent washing step. HRP-labeled tracer 
antibody bound to the well is then incubated with a 
substrate solution and then measured in a 
spectrophotometric microplate reader. The enzymatic 
activity of the tracer antibody bound to the anti-SARS-
CoV-2 IgG on the wall of the microtiter well is 
proportional to the amount of the anti-SARS-CoV-2 IgG 




Elecsys anti-SARS-Cov-2 assay uses a recombinant 
protein representing the nucleocapsid (N) antigen for the 
determination of anti-SARS-CoV-2 antibodies. The test 
consists of two main parts: during first incubation, 20 µl 
of sample forms a sandwich complex with biotinylated 
SARS-CoV-2-specific recombinant antigen and SARS-
CoV-2-specific recombinant antigen labeled with a 
ruthenium complex. After addition of streptavidin-
coated microparticles, the complex becomes bound to 
the solid phase via interaction of biotin and streptavidin. 
Then, the reaction mixture is aspirated into the 
measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. 
Unbound substances are then removed with 
ProCell/ProCell M. Application of voltage to the 
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1 P fever < 38 °C, nasal discharge, fatigue, weakness, loss of taste and smell No P 
2 P fever < 38 °C, loss of taste and smell No P 
3 P fever > 38 °C, loss of taste and smell, diarrhea and headache No / 
4 P fever > 38 °C, loss of taste and smell, diarrhea No / 
5 P fever < 38 °C, fatigue, weakness, headache No P 
6 P No Myocardial infarction  P 
7 P fever > 38 °C, cough, nasal discharge No P 
8 P fever < 38 °C No P 
9 P fever < 38 °C, nasal discharge, loss of taste and smell No N 
10 B No No / 
11 N No No / 
12 N No No / 
13 N No No / 
14 N No No / 
15 N No No / 
16 N No No / 
17 N No No / 
18 N No No / 
19 N No No N 
20 N 
fever < 38 °C, cough, shortness of breath, nasal discharge, fatigue, weakness, 
vomit, diarrhea 
Hashimoto's disease N 
21 P fever > 38 °C, cough, shortness of breath, nasal discharge, fatigue, weakness No / 
22 N fever < 38 °C, cough, shortness of breath, nasal discharge, fatigue, weakness 
Asthma, COPD, immune 
system disorders 
N 
23 N fever < 38 °C, cough, shortness of breath No N 
24 N fever < 38 °C, cough, shortness of breath, fatigue, weakness No N 
25 P No No / 
26 P fever < 38 °C, cough, fatigue, weakness, loss of taste and smell, headache No P 
27 P fever < 38 °C, cough, shortness of breath, fatigue, weakness, chest pain  N 
28 P fever < 38 °C, cough, shortness of breath fatigue, weakness Asthma / 
29 P 
fever > 38 °C, cough, shortness of breath, loss of taste and smell, fatigue, 
weakness 
No P 




Legend: P – positive result; B – borderline result; N – negative result, / - not tested 
 
 
which is measured by a photomultiplier. Results are 
determined by the software by comparing the signal 
obtained from the sample with the signal of the cutoff 
value previously obtained by calibration. The result of a 
sample is given either as reactive (positive for anti-
SARS-CoV-2 antibodies) or non-reactive (negative for 
anti-SARS- CoV-2 antibodies). 
 
 
KEUL-O-TEST SARS-CoV-2 (IgG/IgM) 
The Keul-o-test consists of fixed anti-human IgG and 
IgM antibodies on the surface of the cassette in the IgG 
and IgM test regions. To start a test, two drops of buffer 
and 10 µl of human serum are put one after another in 
the sample region on the surface of the cassette. The 
mixture immediately starts to flow through the 
membrane of cassette due to capillary action. If the 
patient sample contains anti-SARS-CoV-2 antibodies, 
then these antibodies will bind to the antigen present in 
the conjugation pad of the cassette and the complex 
formed will migrate to the membrane-bound anti-human 
IgG and/or IgM. A colored band will appear so the test 




RESULTS AND DISCUSSION 
Based on literature data and the reliability of described 
methods, we used the ELISA test as a reference.11 
The ELISA-based method produced the following 
results: 16 positive samples, 13 negative samples, and 
borderline results for 1 sample were detected. 
The Keul-o-test showed 14 positive samples, 13 
negative samples, and 3 borderline results, while the 
Elecsys anti-SARS-Cov-2 test showed 15 positive, 15 
negative, and no borderline cases (Table 2.). 
Among ELISA positive cases, 13 were confirmed with 
other two tests, while 3 cases showed different results 
using different tests: Patient no. 5 showed positive 
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Table 2. Comparison of immunoassay-based tests results for 






lab- based immunoassay 




1 P P P 
2 P P P 
3 P P P 
4 P P P 
5 P P B 
6 P P P 
7 P P P 
8 P P P 
9 P P P 
10 B N N 
11 N N N 
12 N N N 
13 N N B 
14 N N N 
15 N N N 
16 N N N 
17 N N N 
18 N N B 
19 N P N 
20 N N N 
21 P N P 
22 N N N 
23 N N N 
24 N N N 
25 P N N 
26 P P P 
27 P P P 
28 P P P 
29 P P P 
30 P P P 
Legend: P – positive result; B – borderline result; N – negative result,  
 
 
the rapid test showed a borderline result. This patient 
had an infection confirmed by PCR and showed mild 
symptoms. Such data indicate that the rapid test, in this, 
case, showed lower sensitivity when compared with the 
other two tests. Patient no. 21 showed positive results 
with both ELISA and the rapid test, while autoanalyzer 
results were negative. Clinical data showed symptoms 
associated with COVID-19, and PCR-detection of 
COVID-19 was not done. In this case, the autoanalyzer 
test showed lower sensitivity than the other tests. For 
patient no. 25 results were ELISA positive and negative 
with the other 2 tests. Given that this patient had no 
symptoms, the PCR-test was not done, and that the 
patient was considered healthy overall, this case could 
show both higher ELISA sensitivity than the other two 
tests, or lower specificity than the other two tests. 
Patient no. 10, who was borderline based on the ELISA 
test, showed negative results when tested using the other 
two methods and had no symptoms. This case suggests 
lower specificity of ELISA than the other two tests, 
especially because the autoanalyzer test cannot 
discriminate between different classes of anti-SARS-
Cov-2 immunoglobulins. 
Out of 13 ELISA-based negative cases, 8 patients had 
no symptoms and the PCR-test was not done, while 4 
patients had minor respiratory distress, a fever < 38 °C 
and the PCR test was negative. Among asymptomatic 
patients who had a negative ELISA test, two (no. 13 and 
18) showed borderline results using the rapid test. In 
those cases, the rapid test showed lower specificity than 
the other two tests. Patient no. 19. was asymptomatic, 
had a negative PCR test and was ELISA and rapid test 
negative. In this case the autoanalyzer showed positive 
results that can only be interpreted as false positive. 
Although this study included only 30 cases, it showed 
that serological tests like ELISA and 
electrochemiluminescence immunoassays might give 
false negative or false positive results, and therefore 
should be interpreted only in relation to clinical data and 
a PCR-test that was performed during the acute phase of 
the disease. Taken together, our results suggest that the 
rapid test is the least reliable. 
Moreover, two important points need to be taken into 
account when choosing the optimal immunoassay-based 
test for e. g. epidemiological studies: sensitivity and 
specificity of the tests that depends on antibody classes 
it detects as well as various expected immunological 
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